Stock Ratings / Health Care / SER / financials

ATNM (42) MREO (42) ELTX (31) CTOR (39) ⌘ Pro Terminal →

Serina Therapeutics Inc. (SER) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.89 +15.24% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.94

Serina Therapeutics Inc. (SER) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $48.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.94 (+2.55%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SER)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY SER SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (26% of score)

FRED Regime × Technicals: 18% of 52W Range • RSI-14 at 52.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$2.00-14% Next Q

Q2 (-2Q)

Grade D$1.72-4.1% Next Q

Q3 (-1Q)

Grade D$1.65+14.5% Next Q

Current

Grade D-$1.89-6.7% Hist 90D α

Trajectory: C- (51) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SER Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SER currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.15) and Max Pain ($1.98) forces dealer call-delta covering toward $5.24.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SER• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SER Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SER Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $3.2M

FY24

Rev $56.0K

FY25

Rev $130.0K

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$130.0K	52%	-80%	-$19.2M	-$18.0M	-45%
FY 2024	$56.0K	52%	-80%	-$11.1M	-$17.2M	-45%
FY 2023	$3.2M	52%	-80%	$5.3M	-$2.5M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SER)

✓Walkthrough of SER's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SER // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3.85%📐 HORIZONTAL RANGE

2026-10-30O $1.47H $2.55L $1.47C $1.89VOL 154.9K

RES: $3.65SUP: $1.27SMA50: $2.15SMA200: $2.09

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SER Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SER Butterfly Map → + Track SER →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +132.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SER today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SER. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SER today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SER)

Health Care Rank #553 of 1016 ⚔️ ATNM vs SER Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SER vs. ATNM, MREO, ELTX, CTOR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Serina Therapeutics Inc. (SER) ranks #553 by composite RQD confidence (43/100, grade D-) and #756 by equity capitalization ($48.0M). Within this direct 5-issuer industry benchmark cohort, SER leads on earnings valuation at N/A trailing P/E, while SER leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SER currently leads its immediate peer cohort in composite quantitative strength at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SER ACTIVE Serina Therapeutics Inc.	D-	43/100	—	—	-35.0%	+15.24%	$48.0M	Benchmark Subject
ATNM Actinium Pharmaceuticals Inc. (Delaware)	D-	42/100	—	—	-35.0%	+10.87%	$48.1M	/atnm-vs-ser →
MREO Mereo BioPharma Group plc	D-	42/100	—	—	-35.0%	+1.62%	$48.2M	/mreo-vs-ser →
ELTX Elicio Therapeutics Inc.	E	31/100	—	—	-35.0%	-5.40%	$47.4M	/eltx-vs-ser →
CTOR Citius Oncology Inc.	D-	39/100	—	—	-35.0%	-8.20%	$49.2M	/ctor-vs-ser →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001708599

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Serina Therapeutics Inc. (SER) reported GAAP revenue of $130.0K (+132.1% vs. FY2024 revenue of $56.0K , and -95.9% cumulative change since FY2023) , GAAP net income of -$19.2M, operating cash flow of -$18.0M, and free cash flow of -$18.0M (-5.0% YoY). On the balance sheet, SER closed FY2025 with $7.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$130.0K	-$19.2M	-$18.0M	-$18.0M	$7.0M	—
FY2024 (FY)	2024-12-31	$56.0K	-$11.1M	-$17.1M	-$17.2M	$6.7M	—
FY2023 (FY)	2023-12-31	$3.2M	$5.3M	-$2.5M	-$2.5M	—	—

3. SER Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SER stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Serina Therapeutics Inc. (NYSE: SER) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.89 (+15.24% 1D, market cap $48.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SER ranks #553 in composite RQD confidence.

How does SER compare to ATNM and MREO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SER carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ATNM (Actinium Pharmaceuticals Inc. (Delaware)) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $48.1M) and MREO (Mereo BioPharma Group plc) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $48.2M). Among the 5-stock peer group, SER leads on earnings multiple (N/A) while SER leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SER?

Per SER's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001708599), Serina Therapeutics Inc. generated $130.0K in revenue (+132.1% YoY), -$19.2M in net income, and -$18.0M in free cash flow against $7.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SER trading relative to its 50-day, 200-day, and 52-week technical levels?

SER last traded at $1.89 (+15.24% on volume of 66,352 shares), positioning the stock -12.09% below its 50-day simple moving average ($2.15) and -9.57% below its 200-day simple moving average ($2.09). Across its 52-week range of $1.22 to $4.99, SER sits at the 17.8% percentile with a 14-day RSI of 52.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.65 to $2.13).

SER Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Serina Therapeutics Inc. (SER)?

In FY 2025 (10-K), SER converted $1.0M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: SER RQD Cockpit SER 12M Forecast SER Earnings & Move SER Dividends & DRIP SER Insiders & 13F SER Whale Options SER Profit Sankey SER News & Why